CN103845633A - Traditional Chinese medicine composition for treating dental ulcer and preparation method thereof - Google Patents
Traditional Chinese medicine composition for treating dental ulcer and preparation method thereof Download PDFInfo
- Publication number
- CN103845633A CN103845633A CN201210511276.7A CN201210511276A CN103845633A CN 103845633 A CN103845633 A CN 103845633A CN 201210511276 A CN201210511276 A CN 201210511276A CN 103845633 A CN103845633 A CN 103845633A
- Authority
- CN
- China
- Prior art keywords
- radix
- parts
- mixing
- ethanol
- volatile oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 63
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 208000025865 Ulcer Diseases 0.000 title abstract description 14
- 231100000397 ulcer Toxicity 0.000 title abstract description 13
- 244000197580 Poria cocos Species 0.000 claims abstract description 27
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 27
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 23
- 240000003915 Lophatherum gracile Species 0.000 claims abstract description 19
- 241000735527 Eupatorium Species 0.000 claims abstract description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 179
- 238000002156 mixing Methods 0.000 claims description 87
- 239000007788 liquid Substances 0.000 claims description 59
- 239000000341 volatile oil Substances 0.000 claims description 46
- 238000001035 drying Methods 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 42
- 238000001914 filtration Methods 0.000 claims description 41
- 239000000284 extract Substances 0.000 claims description 27
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 27
- 239000006228 supernatant Substances 0.000 claims description 24
- 208000002399 aphthous stomatitis Diseases 0.000 claims description 23
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 22
- 241000382455 Angelica sinensis Species 0.000 claims description 21
- 229920000858 Cyclodextrin Polymers 0.000 claims description 21
- 229940079593 drug Drugs 0.000 claims description 21
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 21
- 235000011477 liquorice Nutrition 0.000 claims description 18
- 239000001116 FEMA 4028 Substances 0.000 claims description 17
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 17
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 17
- 229960004853 betadex Drugs 0.000 claims description 17
- 208000007117 Oral Ulcer Diseases 0.000 claims description 15
- 238000005507 spraying Methods 0.000 claims description 15
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 13
- 239000008187 granular material Substances 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 12
- 239000006187 pill Substances 0.000 claims description 12
- 238000010298 pulverizing process Methods 0.000 claims description 12
- 238000001816 cooling Methods 0.000 claims description 11
- 239000002671 adjuvant Substances 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 239000011248 coating agent Substances 0.000 claims description 8
- 238000000576 coating method Methods 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 239000003921 oil Substances 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 239000012065 filter cake Substances 0.000 claims description 7
- 229940023488 pill Drugs 0.000 claims description 7
- 241000308663 Eupatorium fortunei Species 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 4
- 244000269722 Thea sinensis Species 0.000 claims description 3
- 239000007938 effervescent tablet Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000006189 buccal tablet Substances 0.000 claims description 2
- 239000007910 chewable tablet Substances 0.000 claims description 2
- 238000007796 conventional method Methods 0.000 claims description 2
- 239000007919 dispersible tablet Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 239000006191 orally-disintegrating tablet Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 229940046011 buccal tablet Drugs 0.000 claims 1
- 229940068682 chewable tablet Drugs 0.000 claims 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract description 12
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract description 12
- 244000061520 Angelica archangelica Species 0.000 abstract description 8
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract description 8
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 abstract description 3
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 abstract description 3
- 244000248557 Ophiopogon japonicus Species 0.000 abstract description 3
- 229940010454 licorice Drugs 0.000 abstract description 3
- 244000081426 Ranunculus ficaria Species 0.000 abstract description 2
- 235000002226 Ranunculus ficaria Nutrition 0.000 abstract description 2
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 33
- 230000000694 effects Effects 0.000 description 25
- 230000002401 inhibitory effect Effects 0.000 description 17
- 241000700159 Rattus Species 0.000 description 15
- 210000000952 spleen Anatomy 0.000 description 14
- 230000000144 pharmacologic effect Effects 0.000 description 12
- 238000011160 research Methods 0.000 description 12
- 241000202726 Bupleurum Species 0.000 description 11
- 210000000214 mouth Anatomy 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 210000003734 kidney Anatomy 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 230000001737 promoting effect Effects 0.000 description 10
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 9
- 210000002216 heart Anatomy 0.000 description 9
- 235000009508 confectionery Nutrition 0.000 description 8
- 235000006484 Paeonia officinalis Nutrition 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 230000000306 recurrent effect Effects 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000736199 Paeonia Species 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 240000000031 Achyranthes bidentata Species 0.000 description 5
- 241000193830 Bacillus <bacterium> Species 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000000242 pagocytic effect Effects 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 206010002198 Anaphylactic reaction Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 208000003455 anaphylaxis Diseases 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 210000002200 mouth mucosa Anatomy 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 230000009285 allergic inflammation Effects 0.000 description 3
- 230000036783 anaphylactic response Effects 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 208000020670 canker sore Diseases 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 239000000679 carrageenan Substances 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 235000014103 egg white Nutrition 0.000 description 3
- 210000000969 egg white Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 3
- 229960004949 glycyrrhizic acid Drugs 0.000 description 3
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 3
- 235000019410 glycyrrhizin Nutrition 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 208000018962 mouth sore Diseases 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- 208000000104 Arthus reaction Diseases 0.000 description 2
- 208000009137 Behcet syndrome Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 206010067510 Contact stomatitis Diseases 0.000 description 2
- 206010015218 Erythema multiforme Diseases 0.000 description 2
- 208000009386 Experimental Arthritis Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010018296 Gingivitis ulcerative Diseases 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- 235000017443 Hedysarum boreale Nutrition 0.000 description 2
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 2
- 208000000440 Herpetic Stomatitis Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061245 Internal injury Diseases 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 206010067152 Oral herpes Diseases 0.000 description 2
- 240000005001 Paeonia suffruticosa Species 0.000 description 2
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 2
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 2
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229940013618 stevioside Drugs 0.000 description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 2
- 235000019202 steviosides Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000605447 Anemarrhena Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010011686 Cutaneous vasculitis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- -1 Gum Acacia Chemical compound 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 241001106477 Paeoniaceae Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
- 244000089486 Phragmites australis subsp australis Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000192023 Sarcina Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010044278 Trace element deficiency Diseases 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 206010047627 Vitamin deficiencies Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229930191283 anemarrhena Natural products 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 235000020803 food preference Nutrition 0.000 description 1
- 235000019256 formaldehyde Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 206010018388 glossodynia Diseases 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000008113 selfheal Nutrition 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 210000001584 soft palate Anatomy 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating dental ulcer and a preparation method thereof. The composition is prepared from radix bupleuri, white peony root, angelica, moutan bark, rhizoma anemarrhenae, figwort, ophiopogon japonicus, poria cocos, eupatorium, radix achyranthis bidentatae, lophatherum gracile and licorice according to a certain weight ratio. The composition is prepared into an oral preparation, and the traditional Chinese medicine composition has a function of treating dental ulcer.
Description
Technical Field
The invention relates to a traditional Chinese medicine composition for treating oral ulcer and a preparation method thereof, belonging to the technical field of traditional Chinese medicines.
Background
Oral ulcer, which is generally called as oral cavity inflammation or aphtha in folk, is a local ulcer injury of oral mucosa which is characterized by recurrent attacks, can self-heal and can occur at any part of the oral mucosa. The mucosa of the lips, the cheeks, the soft palate or the gingiva and the like of the oral cavity is common, single or multiple round or oval ulcers with different sizes occur, the surface is covered with a gray or yellow false membrane, the center is sunken, the boundary is clear, the surrounding mucosa is red and slightly swollen, the local burning pain of the ulcer is obvious, and the oral cavity has the characteristics of periodicity, recurrence and self-limitation. The canker sore is also known as Recurrent Aphthous Stomatitis (RAS), Recurrent Oral Ulcer (ROU), recurrent aphthous ulcer (rohr ahthae) or canker sore. The causes of oral ulcers may be local trauma, stress, changes in food, medication, hormone levels, and vitamin or trace element deficiencies. Systemic diseases, heredity, immunity and microorganisms may play an important role in the development and development of oral ulcers. The treatment is mainly local treatment, and the serious one needs systemic treatment.
The traditional Chinese medicine considers that the oral ulcer has the following causes: firstly, six exogenous pathogens are mainly dryness-heat and fire, dryness-heat is dry and astringent, and tends to damage body fluid, fire is yang-heat, which causes body fluid consumption and burning fire, and aphtha is finally developed. Therefore, canker sores are likely to recur in autumn and when the climate changes suddenly. Secondly, improper diet can lead to endogenous fire-heat, attack along the meridians, fumigate the mouth and tongue, and often damage the yin and fluid of the heart, lung and kidney, resulting in aphtha due to overeating spicy and fat food or food preference. Third, excessive emotional depression, restlessness, insomnia, transformation of fire due to depression of five emotions, hyperactivity of heart-fire, inflammation and burning of the tongue, or the heart-fire moving down to the small intestine and attacking the mouth along the meridians, all of which can cause aphtha of the tongue; or depressed anger, liver qi stagnation, liver qi obstruction, fire transformation due to depression, and dark consumption of yin and blood, which may lead to disorder of the Chong and ren meridians, and mouth sores due to stagnation of qi during menstruation, exuberant liver fire and burning of the tongue and mouth. And fourthly, deficiency of body yin fluid of patients, or yin deficiency due to long-term illness, endogenous deficient fire, burning of mouth and tongue, and even mouth and tongue sores. Fifthly, aphtha is caused by overstrain and internal injury, spleen qi deficiency and spleen qi deficiency due to long-term illness, and water dampness failing to transport; or long-standing transforming into heat, damp-heat steaming upwards, which can also cause aphtha. Even more, spleen qi deficiency impairs spleen yang, spleen yang deficiency, cold-dampness and heat generation, which may cause mouth sores. Sixthly, the deficiency of the natural observation or the chronic use of the medicine can damage the spleen and kidney, the deficiency of the spleen and kidney yang, the internal cold of the yin, the cold-dampness over-soaking the mouth and tongue, the cold congealing and blood stasis, and the mouth and tongue can be sore after a long time. In conclusion, six exogenous pathogenic dry-fire affecting the zang-fu organs and internal injury of the zang-fu organs are the main causes of the disease, and the zang-fu organs are the heart and spleen (stomach).
Disclosure of Invention
The invention aims to provide a novel traditional Chinese medicine composition which has the effects of soothing liver-qi stagnation, clearing heat and cooling blood. Can be used for treating aphtha caused by stagnation of liver-qi and excessive heart-spleen fire, with symptoms of multiple ulcers in oral cavity, circular or elliptical shape, red color, pain, vexation, insomnia, thirsty, yellow urine, dry stool, red tongue, yellow fur, and wiry and rapid pulse; recurrent oral ulcer is seen in the above syndromes.
It is another object of the present invention to provide a process for the preparation of the above composition.
The invention is realized by the following technical scheme:
the invention is prepared from the following raw material medicines in parts by weight: 3-9 parts of radix bupleuri, 6-15 parts of radix paeoniae alba, 6-15 parts of angelica sinensis, 6-15 parts of cortex moutan radicis, 6-15 parts of rhizoma anemarrhenae, 6-15 parts of radix scrophulariae, 6-15 parts of radix ophiopogonis, 6-15 parts of poria cocos, 3-15 parts of eupatorium, 4.5-15 parts of radix achyranthis bidentatae, 2-10 parts of lophatherum gracile and 1.5-9 parts of liquorice.
Preferably: 5-7 parts of radix bupleuri, 8-12 parts of radix paeoniae alba, 10-14 parts of angelica sinensis, 8-12 parts of cortex moutan, 8-12 parts of rhizoma anemarrhenae, 8-12 parts of radix scrophulariae, 8-12 parts of radix ophiopogonis, 10-14 parts of poria cocos, 8-12 parts of eupatorium fortunei, 8-12 parts of radix achyranthis bidentatae, 4-8 parts of lophatherum gracile and 3-7 parts of liquorice.
More preferably: 6 parts of radix bupleuri, 10 parts of radix paeoniae alba, 12 parts of angelica sinensis, 10 parts of moutan bark, 10 parts of rhizoma anemarrhenae, 10 parts of radix scrophulariae, 10 parts of radix ophiopogonis, 12 parts of poria cocos, 10 parts of herba eupatorii, 10 parts of radix achyranthis bidentatae, 6 parts of lophatherum gracile and 6 parts of liquorice.
The raw material medicaments can be any crude drug or combination of any processed product.
The invention is based on the theory of traditional Chinese medicine, adopts the mutual matching formula of the effective medicines to achieve the effects of soothing liver-qi stagnation and clearing heat and cooling blood, and can be used as an effective prescription for treating oral ulcer. Wherein,
bupleurum root, radix bupleuri is bitter in taste and slightly cold in nature. It enters liver and gallbladder meridians. Has the effects of dispelling pathogenic wind, relieving fever, invigorating yang and dispersing stagnated liver qi. Pharmacological research shows that the bupleurum has anti-inflammatory effect, and the active ingredient of the bupleurum saponin has inhibition effect on ankle swelling and connective tissue proliferative inflammation caused by various inflammatory agents. The bupleurum polysaccharide can enhance the phagocytic function of cells, enhance the function of natural killer cells, improve the titer of virus specific antibodies, improve the nuclear transfer rate of lymphocytes and improve the delayed anaphylactic reaction of skin.
White peony root, radix Paeoniae alba is bitter and sour in taste and cool in nature. It enters liver and spleen meridians. Has the effects of nourishing blood, softening liver, relieving pain, astringing yin and arresting sweating. Pharmacological research shows that the white peony root has an anti-inflammatory effect, and the paeoniflorin of the white peony root has a remarkable anti-inflammatory effect on rat foot swelling caused by carrageenan. The influence on immunity is shown in that the total glucosides of paeony have enhancement effect on delayed type hypersensitivity of mice, and in addition, the effects of reducing the titer of adenotrypsin, resisting bacteria and the like are realized; the effect of inhibiting the central nervous system is shown in that paeoniflorin injected into abdominal cavity of mouse can reduce spontaneous activity, prolong sleep time of cyclohexarbital sodium, inhibit writhing reaction caused by acetic acid injected into abdominal cavity and resist convulsion caused by pentylenetetrazol.
Dang Gui is sweet and pungent in flavor. It enters liver, heart and spleen meridians. Has effects of replenishing blood, promoting blood circulation, regulating menstruation, relieving pain, and loosening bowel to relieve constipation. Pharmacological research shows that the influence of the polypeptide on the immune system is that the polypeptide can obviously inhibit the generation of antibodies; the phagocytic function of mouse abdominal cavity macrophages can be obviously enhanced; the angelica neutral oil total acid has the functions of enhancing the phagocytic function of macrophages and promoting the lymphocyte transformation; the angelica polysaccharide has the functions of obviously promoting the formation rate of E-rosette and the positive rate of esterase staining; the total acid has effect in promoting specific antibody IgG production.
Mu Dan Pi is bitter, pungent and slightly cold in flavor. It enters heart, liver and kidney meridians. Has the functions of clearing away heat, cooling blood, promoting blood circulation and dissipating blood stasis. Pharmacological research shows that the tree peony bark has the functions of resisting inflammation and allergic reaction, and the paeonol which is the effective component of the tree peony bark has the inhibiting effect on animal experimental arthritis and allergic inflammation; the paeonol has anti-inflammatory effect on experimental arthritis and otitis, and can reduce permeability of capillary vessel, prevent mouse ulcer disease caused by stress, and inhibit gastric secretion of rat; has weak effects of resisting acetylcholine and histamine for isolated ileum of mouse and guinea pig, and can inhibit spontaneous movement of rat in uterus; the medicine has the effects of inhibiting rat paw swelling and rat pleurisy polymorphonuclear leukocyte migration caused by various medicines; it can be used for inhibiting allergic inflammation such as guinea pig Forssman cutaneous vasculitis, rat reverse skin anaphylaxis, rat active and passive Arthus reaction, and delayed hypersensitivity. The cortex moutan decoction is administered by intragastric administration, and has effects of inhibiting mouse auricle swelling caused by xylene, and rat foot swelling caused by carrageenan, egg white and formaldehyde; it can be used for inhibiting allergic inflammation such as passive skin anaphylaxis, reverse skin anaphylaxis, and Arthus reaction in rat caused by Trichosanthis radix.
Anemarrhena rhizome is bitter and sweet in flavor and cold in nature. It enters lung, stomach and kidney meridians. Has the effects of clearing heat, purging fire, promoting fluid production and moistening dryness. Pharmacological research shows that the rhizoma anemarrhenae has an antibacterial effect, and the rhizoma anemarrhenae decoction has an inhibitory effect on typhoid bacillus, paratyphoid bacillus, dysentery bacillus, escherichia coli, proteus bacillus, vibrio cholerae, staphylococcus and the like.
Figwort root is sweet, bitter, salty and slightly cold in nature. It enters lung, stomach and kidney meridians. Has effects of clearing heat, cooling blood, clearing pathogenic fire, removing toxic substance, and nourishing yin. Pharmacological research shows that radix scrophulariae has antibacterial effect, has inhibitory effect on Staphylococcus aureus, and also has inhibitory effect on various pathogenic and nonpathogenic fungi.
Mai Dong is sweet, slightly bitter and slightly cold in flavor. It enters heart, lung and stomach meridians. Has the effects of nourishing yin, promoting the production of body fluid, moistening lung and clearing away heart-fire. Pharmacological research shows that the fibrous root extract of ophiopogon japonicus has the function of improving cellular immunity. The effect on the central nervous system is shown in that the dwarf lilyturf tuber decoction has a sedative effect, can also enhance the sedative effect of chlorpromazine, enhance the hypnotic effect of pentobarbital sodium and antagonize the excitability of caffeine.
Poria cocos, sweet, bland and neutral. They enter heart, lung, spleen and kidney meridians. Has effects of promoting diuresis, eliminating dampness, invigorating spleen, and calming heart. Pharmacological research shows that the pachyman has the function of enhancing the immune function of normal and tumor-bearing mice and can enhance the phagocytic function of macrophages of the mice.
The eupatorium has pungent taste and mild property. It enters spleen, stomach and lung meridians. Has the effects of relieving summer-heat, eliminating dampness, removing dirt and regulating the middle warmer. Pharmacological research shows that the eupatorium 100% water decoction has effect of inhibiting laryngobacter albus, staphylococcus aureus, sarcina, proteus, typhoid bacillus, etc. by test tube dilution.
Niu xi is bitter and sour in taste and neutral in nature. Liver diseases entering; the kidney channel. Has effects in nourishing liver and kidney, strengthening muscle and bone, promoting blood circulation, dredging channels, purging pathogenic fire (blood), and inducing diuresis for treating stranguria. Pharmacological research shows that achyranthes bidentata has a relatively obvious inhibiting effect on the formaldehyde arthritis of rats; has weak inhibiting effect on egg white arthritis of rats; has obvious effect of promoting inflammation and swelling to subside for the egg white arthritis of the rat.
Lophatherum gracile is sweet and bland in flavor and cold in nature. It enters heart and kidney meridians. Sweet and bland in flavor, warm in nature, clear and descend, and good at guiding heart and small intestine fire downward to induce diuresis and treat stranguria. Pharmacological research shows that the lophatherum gracile decoction has an inhibitory effect on staphylococcus aureus and hemolytic streptococcus in vitro tests.
Licorice root, radix Glycyrrhizae is neutral in nature and sweet in flavor, entering twelve meridians. Has the effects of invigorating spleen and replenishing qi, clearing away heat and toxic materials, eliminating phlegm and relieving cough, relieving spasm and pain, and harmonizing the medicines. Pharmacological research shows that the liquorice has the function of regulating the organism immunity, the liquorice glucan can enhance the organism immunity, has the function of activating and proliferating splenic lymphocytes of mice, shows the characteristic of mitogen, and has the synergistic effect when being used together with ConA. Glycyrrhizic acid mainly has the functions of enhancing phagocytic function of macrophages and enhancing cellular immune function, but has an inhibitory effect on humoral immune function. The licorice also has antibacterial, antiviral, antiinflammatory, and antiallergic effects, and the licorice flavonoids have inhibitory effect on Staphylococcus aureus, Bacillus subtilis, yeast, fungi, streptococcus, etc. Glycyrrhizin has obvious inhibiting effect on Human Immunodeficiency Virus (HIV), hepatitis virus, vesicular stomatitis virus, adenovirus type III, herpes simplex virus type I, vaccinia virus, etc. The Glycyrrhrizae radix has corticoid-like antiinflammatory effect, and can be used for inhibiting mouse chemical auricle swelling, increased permeability of abdominal capillary, rat cotton ball granuloma, formaldehyde rat foot swelling, carrageenan rat arthritis, etc.
When the medicines are used, the medicines which are equivalent to the weight ratio can be respectively cleaned, dried, crushed and mixed to obtain granules or powder with the granularity meeting the preparation requirement for direct administration. The medicines which are equivalent to the weight proportion relation can be used as raw materials, and after proper treatment, the medicines can be added with pharmaceutic adjuvant and made into various preparations according to the needs. In the process of preparing the preparation from the raw material medicines, the raw material medicines can be processed by adopting the following method: extracting with water or ethanol of different concentrations, respectively, concentrating the extractive solution, and drying to obtain crude extract; or further refining by one or more of alcohol precipitation, water dissolution, organic solvent extraction, flocculation precipitation, and column chromatography to obtain refined extract; the specific operation and/or use method for extracting the effective medicinal components can be a mode of respectively extracting the effective medicinal components of the medicinal components in the proportional amounts as raw materials and then mixing the effective medicinal components, or a mode of mixing the medicinal components in the proportional amounts and then extracting the medicinal components together. Different extraction methods, equipment and ideal or optimal extraction temperature, solvent dosage, extraction time, extraction times and other specific conditions required during extraction are adopted, and the extract can be screened and found through experiments according to actual conditions.
The preparation method comprises the following steps:
a) weighing radix bupleuri, radix paeoniae alba, angelica sinensis, cortex moutan, rhizoma anemarrhenae, radix scrophulariae, radix ophiopogonis, poria cocos, eupatorium, radix achyranthis bidentatae, lophatherum gracile and liquorice;
b) extracting volatile oil from radix Angelicae sinensis and herba Eupatorii separately or together, collecting volatile oil in another container, collecting the residue as residue I, and filtering the extractive liquid to obtain liquid I;
c) distilling cortex moutan with water, and mixing the distillate; filtering the distilled liquid medicine to obtain liquid medicine II, and taking the extracted dregs of a decoction as dregs of a decoction II for later use;
d) mixing rhizoma anemarrhenae, radix scrophulariae, radix Ophiopogonis, Poria, folium Bambusae, Glycyrrhrizae radix, residue I and residue II, extracting with water, and mixing extractive solutions to obtain medicinal liquid III;
e) mixing the liquid medicine I, the liquid medicine II and the liquid medicine III, properly concentrating, adding ethanol for precipitation, standing overnight, and taking supernatant for later use;
f) extracting bupleuri radix, radix Paeoniae alba, and Achyranthis radix with 50-90% ethanol, mixing ethanol extractive solutions, mixing with the above supernatant, recovering ethanol, concentrating to obtain soft extract, and drying under reduced pressure to obtain dry extract;
g) spraying the distillate in the step c) into dry paste, dissolving the volatile oil by using a solvent, spraying the dissolved volatile oil into the dry paste or coating the volatile oil, mixing the volatile oil with the dry paste, drying, and crushing into fine powder to prepare the active ingredient of the composition.
The preparation method of the invention can also comprise the following steps:
extracting radix bupleuri, radix paeoniae alba, angelica sinensis, moutan bark, rhizoma anemarrhenae, radix scrophulariae, radix ophiopogonis, poria cocos, eupatorium, radix achyranthis bidentatae, lophatherum gracile and liquorice with water or 40-95% ethanol, combining filtrates, concentrating, drying, and crushing into fine powder to prepare the active ingredients of the composition.
The prepared active ingredients can be directly used as medicines or added with pharmaceutically acceptable auxiliary materials to prepare the required preparation according to the conventional process. For example, the composition can be made into oral medicines in solid preparation forms such as common tablets (dispersible tablets, effervescent tablets, orally disintegrating tablets, buccal tablets, chewable tablets and effervescent tablets), capsules (hard capsules and soft capsules), granules, pills (dripping pills, honey pills, water-honeyed pills and concentrated pills), powder, bagged tea and the like, and can also be made into oral medicines in liquid preparation forms such as syrup, oral liquid and the like. Therefore, the pharmaceutical composition can contain pharmaceutically acceptable auxiliary materials besides the active ingredients.
The auxiliary materials described herein may be different depending on different formulations, such as diluents, disintegrants, excipients, binders, lubricants, surfactants, fillers, etc., which are commonly used in solid formulations such as tablets, capsules, granules, etc.; surfactants, diluents, preservatives, stabilizers, flavoring agents, thickeners, glidants and the like are commonly used in liquid preparation forms such as syrups, oral liquids and the like.
The common adjuvants include starch, lactose, dextrin, sugar powder, microcrystalline cellulose, mannitol, xylitol, polyethylene glycol, calcium sulfate, calcium hydrogen phosphate, calcium carbonate, modified starch, sorbitol, polyvinylpyrrolidone, heavy magnesium carbonate, sodium carboxymethylcellulose, hydroxypropyl methylcellulose, ethyl cellulose, carboxymethyl starch sodium, hydroxypropyl cellulose, polyvidone K30, kaolin, pregelatinized starch, magnesium stearate, pulvis Talci, Gum Acacia, stevioside, betaine, aspartame, glycyrrhizin, saccharin sodium, citric acid, sorbic acid, potassium sorbate, ethylparaben, sucrose, starch syrup, guar gum, stevioside, sodium alginate, maltose, citric acid, malic acid, sucralose, menthol, coffee powder, monoglyceride, magnesium lauryl sulfate, etc.
For the above-mentioned formulations, the preparation method is exemplified as follows:
the granules are prepared by the following method:
adding 6-10 times of water into radix Angelicae sinensis and herba Eupatorii, extracting volatile oil for 6 hr, filtering the medicinal liquid after oil extraction to obtain medicinal liquid I, collecting the residue, clathrating the volatile oil with beta-cyclodextrin, refrigerating overnight, filtering, and drying the filter cake at low temperature to obtain clathrate of volatile oil beta-cyclodextrin; adding 4-10 times of water into cortex moutan, distilling for 1-5 hr, collecting distillate, and collecting the distillate to obtain medicinal liquid II and medicinal residue II; mixing rhizoma anemarrhenae, radix scrophulariae, radix Ophiopogonis, Poria, folium Bambusae, Glycyrrhrizae radix, residue I and residue II, decocting with 6-10 times of water for 1-3 times, each for 1-3 hr, mixing extractive solutions, mixing the extractive solutions with the medicinal liquid I and the medicinal liquid II, concentrating to relative density of 1.10-1.15 at 60 deg.C, cooling, adding ethanol to ethanol content of 50-80%, standing overnight, and filtering to obtain supernatant; extracting bupleuri radix, radix Paeoniae alba and Achyranthis radix with 6-10 times of 50-90% ethanol for 1-3 times, each time for 1-3 hr, mixing extractive solutions, filtering, mixing filtrate with the above supernatant, recovering ethanol until no alcohol smell exists, concentrating to obtain soft extract with relative density of 1.30-1.35 at 60 deg.C, drying under reduced pressure to obtain dry extract, spraying cortex moutan distillate, mixing with volatile oil times of cyclodextrin clathrate, drying, pulverizing into fine powder, adding appropriate amount of adjuvants, granulating, drying, and grading to obtain granule.
The above preparation method is only illustrative of the preparation method of the present invention, but it should not be understood that the preparation method of the present invention is limited to the above-listed method.
From the foregoing, it will be apparent that various other modifications, substitutions and variations can be made in the present invention without departing from the basic technical spirit of the invention, as defined by the common technical knowledge and common practice in the art.
Detailed Description
The beneficial effects of the compositions according to the invention are further illustrated by the following test examples:
1. test materials
Drug group: the examples 1, 2 and 3 of the present invention are drug group 1, drug group 2 and drug group 3, respectively, and are administered orally.
Control group: yumai oropharynx mixture, for oral administration.
2. Test method
320 out-patient cases were selected, 160 men, 160 women, the largest age 75 years, and the smallest age 16 years. The observation indexes are as follows: recurrent oral ulcer major symptomatic type: behcet's disease, oral mucosa injury ulcer, herpetic stomatitis, erythema multiforme, tuberculous ulcer, contact stomatitis, necrotizing gingivitis and malignant ulcer. The symptom selection criteria were: behcet's disease, oral mucosa lesion ulcer, herpetic stomatitis, erythema multiforme, tuberculous ulcer, contact stomatitis, necrotizing gingivitis, and malignant ulcer.
As a result: see table 1.
TABLE 1 comparison of before and after treatment with drugs
P <0.05, P <0.01, compared to control
Inventive examples 4-10 were similarly tested as described above, with the same results as described above.
3. Conclusion
In conclusion, the composition has a remarkable curative effect on treating recurrent oral ulcer, and the effect of treating the oral ulcer is prompted.
The present invention will be described in further detail with reference to the following examples. It should not be understood that the scope of the above-described subject matter of the present invention is limited to the following examples. All the technologies realized based on the above contents of the present invention belong to the scope of the present invention.
Example 1
Bupleurum root 65g white peony root 100g Chinese angelica root 115g bark of peony root 100g
110g of rhizoma anemarrhenae, 100g of radix scrophulariae, 100g of radix ophiopogonis, 100g of poria cocos, and 120g of poria cocos
Herba Eupatorii 95g, Achyranthis radix 100g, herba Lophatheri 55g, Glycyrrhrizae radix 60g
a) Weighing radix bupleuri, radix paeoniae alba, angelica sinensis, cortex moutan, rhizoma anemarrhenae, radix scrophulariae, radix ophiopogonis, poria cocos, eupatorium, radix achyranthis bidentatae, lophatherum gracile and liquorice;
b) extracting radix Angelicae sinensis and herba Eupatorii with 8 times of water for 6 hr, collecting volatile oil in another container, collecting the residue as residue I, and filtering the extractive solution to obtain solution I;
c) adding 6 times of water into cortex moutan, distilling for 4 hr, and mixing the distillate; filtering the distilled liquid medicine to obtain liquid medicine II, and taking the extracted dregs of a decoction as dregs of a decoction II for later use;
d) mixing rhizoma anemarrhenae, radix scrophulariae, radix Ophiopogonis, Poria, folium Bambusae, Glycyrrhrizae radix, residue I and residue II, extracting with 8 times of water for 2 times, each time for 2 hr, and mixing extractive solutions to obtain medicinal liquid III;
e) mixing the medicinal liquid I, II and III, concentrating to relative density of 1.10-1.15 at 60 deg.C, adding ethanol to make ethanol content reach 75%, standing overnight, and collecting supernatant;
f) extracting bupleuri radix, radix Paeoniae alba, and Achyranthis radix with 8 times of 75% ethanol for 2 times, each for 2 hr, mixing ethanol extractive solutions, mixing with the above supernatant, recovering ethanol, concentrating to obtain soft extract with relative density of 1.30-1.35 at 60 deg.C, and drying under reduced pressure to obtain dry extract;
g) spraying the distillate in the step c) into the dry paste, clathrating the volatile oil, mixing with the dry paste, drying, pulverizing into fine powder, adding appropriate amount of adjuvants, granulating, drying, and grading to obtain granule.
Example 2
Bupleurum root 90g white peony root 60g Chinese angelica root 150g bark of peony root 60g
150g of rhizoma anemarrhenae, 60g of radix scrophulariae, 150g of radix ophiopogonis, 60g of poria cocos, and 60g of radix ophiopogonis
Herba Eupatorii 150g, Achyranthis radix 45g, herba Lophatheri 100g, Glycyrrhrizae radix 15g
a) Weighing radix bupleuri, radix paeoniae alba, angelica sinensis, cortex moutan, rhizoma anemarrhenae, radix scrophulariae, radix ophiopogonis, poria cocos, eupatorium, radix achyranthis bidentatae, lophatherum gracile and liquorice;
b) extracting radix Angelicae sinensis and herba Eupatorii with 6 times of water respectively for 6 hr, collecting volatile oil, mixing the residues to obtain residue I, filtering the extractive solution, and mixing to obtain solution I;
c) adding 4 times of water into cortex moutan, distilling for 5 hr, and mixing the distillate; filtering the distilled liquid medicine to obtain liquid medicine II, and taking the extracted dregs of a decoction as dregs of a decoction II for later use;
d) mixing rhizoma anemarrhenae, radix scrophulariae, radix Ophiopogonis, Poria, folium Bambusae, Glycyrrhrizae radix, residue I and residue II, extracting with 10 times of water for 1 time, each time for 3 hr, and mixing extractive solutions to obtain medicinal liquid III;
e) mixing the medicinal liquid I, II and III, concentrating to relative density of 1.10-1.15 at 60 deg.C, adding ethanol to ethanol content of 50%, standing overnight, and collecting supernatant;
f) extracting bupleuri radix, radix Paeoniae alba, and Achyranthis radix with 6 times of 50% ethanol for 3 times, each for 1 hr, mixing ethanol extractive solutions, mixing with the above supernatant, recovering ethanol, concentrating to obtain soft extract with relative density of 1.30-1.35 at 60 deg.C, and drying under reduced pressure to obtain dry extract;
g) spraying the distillate in step c) into the dry extract, dissolving the volatile oil with ethanol, spraying the dissolved volatile oil into the dry extract, drying, pulverizing into fine powder, adding appropriate amount of adjuvants, granulating, drying, and grading to obtain granule.
Example 3
Radix bupleuri 30g, radix paeoniae alba 150g, angelica sinensis 60g and cortex moutan 150g
60g of rhizoma anemarrhenae, 150g of radix scrophulariae, 60g of radix ophiopogonis, 150g of poria cocos, and 150g of radix ophiopogonis
30g of eupatorium fortunei, 150g of achyranthes bidentata, 20g of lophatherum gracile and 90g of liquorice
a) Weighing radix bupleuri, radix paeoniae alba, angelica sinensis, cortex moutan, rhizoma anemarrhenae, radix scrophulariae, radix ophiopogonis, poria cocos, eupatorium, radix achyranthis bidentatae, lophatherum gracile and liquorice;
b) extracting radix Angelicae sinensis and herba Eupatorii with 10 times of water for 6 hr, collecting volatile oil in another container, collecting the residue as residue I, and filtering the extractive solution to obtain solution I;
c) adding 10 times of water into cortex moutan, distilling for 1 hr, and mixing the distillate; filtering the distilled liquid medicine to obtain liquid medicine II, and taking the extracted dregs of a decoction as dregs of a decoction II for later use;
d) mixing rhizoma anemarrhenae, radix scrophulariae, radix Ophiopogonis, Poria, folium Bambusae, Glycyrrhrizae radix, residue I and residue II, extracting with 6 times of water for 3 times, each for 1 hr, and mixing the extractive solutions to obtain medicinal liquid III;
e) mixing the medicinal liquid I, II and III, concentrating to relative density of 1.10-1.15 at 60 deg.C, adding ethanol to reach ethanol content of 80%, standing overnight, and collecting supernatant;
f) extracting bupleuri radix, radix Paeoniae alba, and Achyranthis radix with 10 times of 90% ethanol for 1 time, each for 3 hr, mixing ethanol extractive solutions, mixing with the above supernatant, recovering ethanol, concentrating to obtain soft extract with relative density of 1.30-1.35 at 60 deg.C, and drying under reduced pressure to obtain dry extract;
g) spraying the distillate in the step c) into the dry paste, clathrating the volatile oil, mixing with the dry paste, drying, pulverizing into fine powder, adding appropriate amount of adjuvants, granulating, drying, and grading to obtain granule.
Example 4
Bupleurum root 60g white peony root 105g Chinese angelica root 105g bark of peony root 105g
105g of rhizoma anemarrhenae, 105g of radix scrophulariae, 105g of radix ophiopogonis, 105g of poria cocos, 105g of radix ophiopogonis
Herba Eupatorii 90g, Achyranthis radix 95g, herba Lophatheri 60g, radix Glycyrrhizae Preparata 55g
Adding 8 times of water into the angelica and the eupatorium, extracting volatile oil for 6 hours, filtering the liquid medicine after oil extraction to obtain liquid medicine I for later use, using the extracted dregs as dregs I for later use, coating the volatile oil with beta-cyclodextrin, refrigerating overnight, filtering, and drying a filter cake at low temperature to obtain a volatile oil beta-cyclodextrin inclusion compound for later use; adding 8 times of water into cortex moutan, distilling for 4 hr, collecting distillate, and collecting the distillate to obtain medicinal liquid II and medicinal residue II; mixing rhizoma anemarrhenae, radix scrophulariae, radix Ophiopogonis, Poria, folium Bambusae, Glycyrrhrizae radix with residue I and residue II, decocting with 8 times of water for 2 times, each time for 2 hr, mixing extractive solutions, mixing the extractive solutions with the residue I and the residue II, concentrating to relative density of 1.10-1.15 at 60 deg.C, cooling, adding ethanol to ethanol content of 60%, standing overnight, and filtering to obtain supernatant; extracting bupleuri radix, radix Paeoniae alba and Achyranthis radix with 10 times of 70% ethanol for 2 times, each for 2 hr, filtering, mixing the filtrate with the above supernatant, recovering ethanol, concentrating, spraying cortex moutan distillate, adding the volatile oil-times of cyclodextrin clathrate, adding appropriate amount of suspension, flavoring agent and antiseptic, mixing, adding water to desired volume, filtering, and packaging to obtain oral liquid preparation.
Example 5
Radix bupleuri 70g, radix paeoniae alba 80g, wine angelica sinensis 140g and cortex moutan radicis 80g
120g of rhizoma anemarrhenae, 80g of radix scrophulariae, 120g of radix ophiopogonis, 120g of poria cocos, and 100g of poria cocos
Herba Eupatorii 120g, Achyranthis radix 80g, herba Lophatheri 80g, radix Glycyrrhizae Preparata 30g
Adding 10 times of water into the angelica and the eupatorium, extracting volatile oil for 6 hours, filtering the liquid medicine after oil extraction to obtain liquid medicine I for later use, using the extracted dregs as dregs I for later use, coating the volatile oil with beta-cyclodextrin, refrigerating overnight, filtering, and drying a filter cake at low temperature to obtain a volatile oil beta-cyclodextrin inclusion compound for later use; adding 4 times of water into cortex moutan, distilling for 5 hr, collecting distillate, and collecting the distillate to obtain medicinal liquid II and medicinal residue II; mixing rhizoma anemarrhenae, radix scrophulariae, radix Ophiopogonis, Poria, folium Bambusae, Glycyrrhrizae radix with residue I and residue II, decocting with 6 times of water for 3 times, each time for 2 hr, mixing extractive solutions, mixing the extractive solutions with the residue I and the residue II, concentrating to relative density of 1.10-1.15 at 60 deg.C, cooling, adding ethanol to ethanol content of 65%, standing overnight, and filtering to obtain supernatant; extracting bupleuri radix, radix Paeoniae alba and Achyranthis radix with 9 times of 60% ethanol for 2 times, each for 3 hr, mixing extractive solutions, filtering, mixing filtrate with the above supernatant, recovering ethanol to remove ethanol smell, concentrating to obtain soft extract with relative density of 1.30-1.35 at 60 deg.C, drying under reduced pressure to obtain dry extract, spraying cortex moutan distillate, mixing with volatile oil times of cyclodextrin clathrate, drying, pulverizing into fine powder, granulating, drying, and grading to obtain granule.
Example 6
Bupleurum root 50g white peony root 120g Chinese angelica root 100g bark of peony root 120g
80g of rhizoma anemarrhenae, 120g of radix scrophulariae, 80g of radix ophiopogonis, 80g of poria cocos, 140g of poria cocos
Herba Eupatorii 80g achyranthis bidentatae charcoal 120g lophatherum gracile 40g liquorice 70g
Adding 7 times of water into the angelica and the eupatorium, extracting volatile oil for 6 hours, filtering the liquid medicine after oil extraction to obtain liquid medicine I for later use, using the extracted dregs as dregs I for later use, coating the volatile oil with beta-cyclodextrin, refrigerating overnight, filtering, and drying a filter cake at low temperature to obtain a volatile oil beta-cyclodextrin inclusion compound for later use; adding 5 times of water into cortex moutan, distilling for 3 hr, collecting distillate, and collecting the distillate to obtain medicinal liquid II and medicinal residue II; mixing rhizoma anemarrhenae, radix scrophulariae, radix Ophiopogonis, Poria, folium Bambusae, Glycyrrhrizae radix with residue I and residue II, decocting with 9 times of water for 2 times, each time for 1 hr, mixing extractive solutions, mixing the extractive solutions with the residue I and the residue II, concentrating to relative density of 1.10-1.15 at 60 deg.C, cooling, adding ethanol to ethanol content of 55%, standing overnight, and filtering to obtain supernatant; extracting bupleuri radix, radix Paeoniae alba and Achyranthis radix with 6 times of 70% ethanol for 3 times, each time for 1 hr, mixing extractive solutions, filtering, mixing filtrate with the above supernatant, recovering ethanol to remove ethanol smell, concentrating to obtain soft extract with relative density of 1.30-1.35 at 60 deg.C, drying under reduced pressure to obtain dry extract, spraying cortex moutan distillate, mixing with volatile oil BETA-cyclodextrin clathrate, drying, pulverizing into fine powder, mixing, granulating, drying, and making into capsule.
Example 7
Bupleurum root 40g white peony root 95g Chinese angelica root 130g prepared moutan bark 140g
140g of rhizoma anemarrhenae, 70g of radix scrophulariae, 80g of radix ophiopogonis, 70g of poria cocos, and 70g of radix ophiopogonis
140g of eupatorium fortunei, 50g of achyranthes bidentata, 30g of lophatherum gracile and 20g of honey-fried licorice root
Adding 9 times of water into the angelica and the eupatorium, extracting volatile oil for 6 hours, filtering the liquid medicine after oil extraction to obtain liquid medicine I for later use, using the extracted dregs as dregs I for later use, coating the volatile oil with beta-cyclodextrin, refrigerating overnight, filtering, and drying a filter cake at low temperature to obtain a volatile oil beta-cyclodextrin inclusion compound for later use; adding 7 times of water into cortex moutan, distilling for 2 hr, collecting distillate, and collecting the distillate to obtain medicinal liquid II and medicinal residue II; mixing rhizoma anemarrhenae, radix scrophulariae, radix Ophiopogonis, Poria, folium Bambusae, Glycyrrhrizae radix with residue I and residue II, decocting with 7 times of water for 2 times, each time for 2 hr, mixing extractive solutions, mixing the extractive solutions with the residue I and the residue II, concentrating to relative density of 1.10-1.15 at 60 deg.C, cooling, adding ethanol to ethanol content of 60%, standing overnight, and filtering to obtain supernatant; extracting bupleuri radix, radix Paeoniae alba and Achyranthis radix with 9 times of 85% ethanol for 1-3 times, each time for 1-3 hr, mixing extractive solutions, filtering, mixing filtrate with the above supernatant, recovering ethanol until no alcohol smell exists, concentrating to obtain soft extract with relative density of 1.30-1.35 at 60 deg.C, drying under reduced pressure to obtain dry extract, spraying cortex moutan distillate, mixing with volatile oil BETA-cyclodextrin clathrate, drying, pulverizing into fine powder, adding appropriate amount of excipient and filler, mixing, granulating, drying, adding lubricant, mixing, tabletting, and optionally coating to obtain tablet.
Example 8
Bupleurum root 85g white peony root 125g Chinese angelica root 70g bark of peony root 70g
70g of rhizoma anemarrhenae, 140g of radix scrophulariae, 140g of radix ophiopogonis, 140g of poria cocos, 140g of radix ophiopogonis
40g of eupatorium fortunei, 140g of achyranthes bidentata, 90g of lophatherum gracile, 85g of liquorice
Adding 8 times of water into the angelica and the eupatorium, extracting volatile oil for 6 hours, filtering the liquid medicine after oil extraction to obtain liquid medicine I for later use, using the extracted dregs as dregs I for later use, coating the volatile oil with beta-cyclodextrin, refrigerating overnight, filtering, and drying a filter cake at low temperature to obtain a volatile oil beta-cyclodextrin inclusion compound for later use; adding 8 times of water into cortex moutan, distilling for 2 hr, collecting distillate, and collecting the distillate to obtain medicinal liquid II and medicinal residue II; mixing rhizoma anemarrhenae, radix scrophulariae, radix Ophiopogonis, Poria, folium Bambusae, Glycyrrhrizae radix with residue I and residue II, decocting with 8 times of water for 2 times, each time for 2 hr, mixing extractive solutions, mixing the extractive solutions with the residue I and the residue II, concentrating to relative density of 1.10-1.15 at 60 deg.C, cooling, adding ethanol to ethanol content of 70%, standing overnight, and filtering to obtain supernatant; extracting bupleuri radix, radix Paeoniae alba and Achyranthis radix with 8 times of 60% ethanol for 2 times, each time for 1.5 hr, mixing extractive solutions, filtering, mixing filtrate with the above supernatant, recovering ethanol until no alcohol smell is present, concentrating to obtain soft extract with relative density of 1.30-1.35 at 60 deg.C, drying under reduced pressure to obtain dry extract, spraying cortex moutan distillate, mixing with volatile oil BETA-cyclodextrin clathrate, drying, pulverizing into fine powder, and making into bagged tea by conventional method.
Example 9
Bupleurum root 80g white peony root 95g Chinese angelica root 120g bark of peony root 130g
130g of rhizoma anemarrhenae, 130g of radix scrophulariae, 130g of radix ophiopogonis, 130g of poria cocos, 100g of poria cocos
Herba Eupatorii 120g, Achyranthis radix 120g, herba Lophatheri 50g, Glycyrrhrizae radix 50g
Decocting the above 12 materials in water, filtering, mixing filtrates, concentrating, drying, pulverizing into fine powder, adding appropriate amount of adjuvant, mixing, and making into pill.
Example 10
35g of radix bupleuri, 65g of white peony root, 90g of angelica sinensis and 90g of moutan bark
75g of rhizoma anemarrhenae, 110g of radix scrophulariae, 110g of radix ophiopogonis, 110g of poria cocos, and 110g of radix ophiopogonis
50g of eupatorium fortunei, 110g of achyranthes bidentata, 25g of lophatherum gracile, 25g of liquorice and 30g of liquorice
Extracting the above 12 materials with 70% ethanol, filtering, mixing ethanol extractive solutions, recovering ethanol until no ethanol smell exists, concentrating under reduced pressure, drying, pulverizing into fine powder, adding appropriate amount of adjuvant or no adjuvant, mixing, and making into powder.
Claims (10)
1. A traditional Chinese medicine composition for treating oral ulcer and a preparation method thereof are characterized in that the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 3-9 parts of radix bupleuri, 6-15 parts of radix paeoniae alba, 6-15 parts of angelica sinensis, 6-15 parts of cortex moutan radicis, 6-15 parts of rhizoma anemarrhenae, 6-15 parts of radix scrophulariae, 6-15 parts of radix ophiopogonis, 6-15 parts of poria cocos, 3-15 parts of eupatorium, 4.5-15 parts of radix achyranthis bidentatae, 2-10 parts of lophatherum gracile and 1.5-9 parts of liquorice.
2. The traditional Chinese medicine composition for treating oral ulcer and the preparation method thereof according to claim 1 are characterized by being prepared from the following raw materials in parts by weight: 5-7 parts of radix bupleuri, 8-12 parts of radix paeoniae alba, 10-14 parts of angelica sinensis, 8-12 parts of cortex moutan, 8-12 parts of rhizoma anemarrhenae, 8-12 parts of radix scrophulariae, 8-12 parts of radix ophiopogonis, 10-14 parts of poria cocos, 8-12 parts of eupatorium fortunei, 8-12 parts of radix achyranthis bidentatae, 4-8 parts of lophatherum gracile and 3-7 parts of liquorice.
3. A method for preparing a Chinese medicinal composition as claimed in claim 1 or 2, which is prepared by:
a) weighing radix bupleuri, radix paeoniae alba, angelica sinensis, cortex moutan, rhizoma anemarrhenae, radix scrophulariae, radix ophiopogonis, poria cocos, eupatorium, radix achyranthis bidentatae, lophatherum gracile and liquorice;
b) extracting volatile oil from radix Angelicae sinensis and herba Eupatorii separately or together, collecting volatile oil in another container, collecting the residue as residue I, and filtering the extractive liquid to obtain liquid I;
c) distilling cortex moutan with water, and mixing the distillate; filtering the distilled liquid medicine to obtain liquid medicine II, and taking the extracted dregs of a decoction as dregs of a decoction II for later use;
d) mixing rhizoma anemarrhenae, radix scrophulariae, radix Ophiopogonis, Poria, folium Bambusae, Glycyrrhrizae radix, residue I and residue II, extracting with water, and mixing extractive solutions to obtain medicinal liquid III;
e) mixing the liquid medicine I, the liquid medicine II and the liquid medicine III, properly concentrating, adding ethanol for precipitation, standing overnight, and taking supernatant for later use;
f) extracting bupleuri radix, radix Paeoniae alba, and Achyranthis radix with 50-90% ethanol, mixing ethanol extractive solutions, mixing with the above supernatant, recovering ethanol, concentrating to obtain soft extract, and drying under reduced pressure to obtain dry extract;
g) spraying the distillate in the step c) into dry paste, dissolving the volatile oil by using a solvent, spraying the dissolved volatile oil into the dry paste or coating the volatile oil, mixing the volatile oil with the dry paste, drying, and crushing into fine powder to prepare the active ingredient of the composition.
4. The preparation method of the traditional Chinese medicine composition according to claim 3, characterized in that the prepared active ingredients are prepared into a pharmaceutically acceptable preparation by a conventional process with or without auxiliary materials.
5. The preparation of the Chinese medicinal composition as claimed in claim 4, wherein the preparation is in the form of tablet, capsule, granule, pill, powder, oral liquid, or bagged tea.
6. The preparation of claim 5, wherein the tablet is a general tablet, a dispersible tablet, an effervescent tablet, an orally disintegrating tablet, a buccal tablet, a chewable tablet; the capsule is hard capsule or soft capsule; the pill is dripping pill, honeyed pill, water-honeyed pill, or concentrated pill.
7. The method for preparing a Chinese medicinal composition according to claim 1 or 2, wherein the Chinese medicinal composition is prepared by extracting bupleuri radix, radix Paeoniae alba, radix Angelicae sinensis, cortex moutan, rhizoma anemarrhenae, radix scrophulariae, radix Ophiopogonis, Poria, herba Eupatorii, Achyranthis radix, folium Bambusae, and Glycyrrhrizae radix with water or 40-95% ethanol, mixing filtrates, concentrating, drying, pulverizing into fine powder, optionally adding adjuvants, and making into pharmaceutically acceptable preparations by conventional method.
8. The formulation of claim 5, wherein said formulation is in the form of granules.
9. The formulation of claim 8, wherein the granules are prepared by:
adding 6-10 times of water into radix Angelicae sinensis and herba Eupatorii, extracting volatile oil for 6 hr, filtering the medicinal liquid after oil extraction to obtain medicinal liquid I, collecting the residue, clathrating the volatile oil with beta-cyclodextrin, refrigerating overnight, filtering, and drying the filter cake at low temperature to obtain clathrate of volatile oil beta-cyclodextrin; adding 4-10 times of water into cortex moutan, distilling for 1-5 hr, collecting distillate, and collecting the distillate to obtain medicinal liquid II and medicinal residue II; mixing rhizoma anemarrhenae, radix scrophulariae, radix Ophiopogonis, Poria, folium Bambusae, Glycyrrhrizae radix, residue I and residue II, decocting with 6-10 times of water for 1-3 times, each for 1-3 hr, mixing extractive solutions, mixing the extractive solutions with the medicinal liquid I and the medicinal liquid II, concentrating to relative density of 1.10-1.15 at 60 deg.C, cooling, adding ethanol to ethanol content of 50-80%, standing overnight, and filtering to obtain supernatant; extracting bupleuri radix, radix Paeoniae alba and Achyranthis radix with 6-10 times of 50-90% ethanol for 1-3 times, each time for 1-3 hr, mixing extractive solutions, filtering, mixing filtrate with the above supernatant, recovering ethanol until no alcohol smell exists, concentrating to obtain soft extract with relative density of 1.30-1.35 at 60 deg.C, drying under reduced pressure to obtain dry extract, spraying cortex moutan distillate, mixing with volatile oil times of cyclodextrin clathrate, drying, pulverizing into fine powder, adding appropriate amount of adjuvants, granulating, drying, and grading to obtain granule.
10. Use of a composition according to claim 1 or 2 for the manufacture of a medicament for the treatment of oral ulcer disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210511276.7A CN103845633B (en) | 2012-12-03 | 2012-12-03 | It is a kind of to treat Chinese medicine composition of canker sore and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210511276.7A CN103845633B (en) | 2012-12-03 | 2012-12-03 | It is a kind of to treat Chinese medicine composition of canker sore and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103845633A true CN103845633A (en) | 2014-06-11 |
| CN103845633B CN103845633B (en) | 2017-08-25 |
Family
ID=50854037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210511276.7A Active CN103845633B (en) | 2012-12-03 | 2012-12-03 | It is a kind of to treat Chinese medicine composition of canker sore and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103845633B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104274688A (en) * | 2014-09-15 | 2015-01-14 | 吴传明 | Traditional Chinese medicine composition for treating oral ulcer |
| CN105031339A (en) * | 2015-07-15 | 2015-11-11 | 张光军 | Traditional Chinese medicine composition for treating stomatitis |
| CN112353739A (en) * | 2020-11-23 | 2021-02-12 | 上海健康医学院 | Chinese herbal medicine toothpaste and production method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101618155A (en) * | 2009-08-05 | 2010-01-06 | 辛保山 | Medicine for curing oral mucosal disease |
| CN101822780A (en) * | 2010-05-26 | 2010-09-08 | 赵晚乐 | Medicament for treating oral ulcer and preparation method thereof |
| CN101919976A (en) * | 2010-07-26 | 2010-12-22 | 荣成市科学技术情报研究所 | Traditional Chinese medicine composition for treating mouth and tongue ulcer |
| CN101985026A (en) * | 2010-10-26 | 2011-03-16 | 朱新华 | Pure Chinese medicinal preparation for rapidly treating halitosis |
-
2012
- 2012-12-03 CN CN201210511276.7A patent/CN103845633B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101618155A (en) * | 2009-08-05 | 2010-01-06 | 辛保山 | Medicine for curing oral mucosal disease |
| CN101822780A (en) * | 2010-05-26 | 2010-09-08 | 赵晚乐 | Medicament for treating oral ulcer and preparation method thereof |
| CN101919976A (en) * | 2010-07-26 | 2010-12-22 | 荣成市科学技术情报研究所 | Traditional Chinese medicine composition for treating mouth and tongue ulcer |
| CN101985026A (en) * | 2010-10-26 | 2011-03-16 | 朱新华 | Pure Chinese medicinal preparation for rapidly treating halitosis |
Non-Patent Citations (1)
| Title |
|---|
| 刘金凤等: "复发性口腔溃疡的中医药治疗进展", 《中医研究》, vol. 15, no. 2, 30 April 2002 (2002-04-30), pages 48 - 51 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104274688A (en) * | 2014-09-15 | 2015-01-14 | 吴传明 | Traditional Chinese medicine composition for treating oral ulcer |
| CN105031339A (en) * | 2015-07-15 | 2015-11-11 | 张光军 | Traditional Chinese medicine composition for treating stomatitis |
| CN112353739A (en) * | 2020-11-23 | 2021-02-12 | 上海健康医学院 | Chinese herbal medicine toothpaste and production method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103845633B (en) | 2017-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100532703B1 (en) | Composition comprising a crude drug complex for preventing and treating gastrointestinal dyskinetic disease | |
| CN103446450B (en) | A kind of composition and method of making the same with alleviating physical fatigue function | |
| CN102488849B (en) | Traditional Chinese medicine composition used for treating periodontitis | |
| CN102370687B (en) | A kind of compound Chinese medicinal preparation for treating colitis and preparation method thereof | |
| CN103845633B (en) | It is a kind of to treat Chinese medicine composition of canker sore and preparation method thereof | |
| CN105055950A (en) | Chinese herbal preparation for treating recurrent oral ulceration and preparation method of Chinese herbal preparation | |
| CN114470114A (en) | Application of Mailuoshutong preparation in preparation of medicine for treating constipation | |
| CN103751579B (en) | Treatment nasopharyngeal carcinoma radiotherapy pharmaceutical composition causing oral mucositis and preparation method thereof | |
| CN101129720B (en) | Compound medicament for treating ankylosing spondylitis | |
| CN1985921B (en) | Chinese medicine composition for treating common cold and its preparing method | |
| CN108478622B (en) | Composition for preventing and treating oral ulcer and preparation method and application thereof | |
| CN109350670A (en) | The preparation method of Ynxingchao dropping pills compound | |
| CN104998162A (en) | Medicine for treating cough and preparing method of medicine | |
| CN101199606B (en) | Medicament for treating liver disease | |
| CN101564424B (en) | Common lamiophlomis root chewable tablet and preparation thereof | |
| CN100506260C (en) | Compound preparation for treating mucosa ulceration | |
| CN107343926B (en) | Traditional Chinese medicine composition for treating recurrent oral ulcer | |
| CN102755519B (en) | Kudzuvine root-kudzuvine flower anti-canker sore particle and preparation method thereof | |
| CN101549140B (en) | Traditional Chinese medicine composition for treating AIDS and preparation method thereof | |
| CN111759901B (en) | Traditional Chinese medicine composition for treating functional abdominal pain of children and preparation method thereof | |
| CN1285372C (en) | Chinese medicine oral preparation for treating gynecologic inflammation and its preparation method | |
| CN106692496B (en) | Compound traditional Chinese medicine buccal tablet and preparation method and application thereof | |
| CN108653460B (en) | Traditional Chinese medicine composition for treating chronic urticaria and preparation method thereof | |
| CN103463453A (en) | Dendrobium stem tablets and extraction and preparation methods thereof | |
| CN104337898B (en) | A kind of Chinese medicine composition of the treatment gout containing Semen Pruni |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 4002 Applicant after: BEIJING INCREASE PHARMACEUTICAL INSTITUTE Co.,Ltd. Address before: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 4002 Applicant before: BEIJING INCREASE PHARMACEUTICAL RESEARCH INSTITUTE Co.,Ltd. Address after: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 4002 Applicant after: BEIJING INCREASE PHARMACEUTICAL RESEARCH INSTITUTE Co.,Ltd. Address before: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 4002 Applicant before: BEIJING INCREASE PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
| COR | Change of bibliographic data | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: Double camp 102299 West Road Beijing city Changping District Science Park No. 79, No. 24 building 6 layer cloud Valley Park Patentee after: Beijing Increasepharm Co.,Ltd. Address before: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 4002 Patentee before: BEIJING INCREASE PHARMACEUTICAL INSTITUTE Co.,Ltd. |